Spectrometer for the pharmaceutical industry GlycoTyper

R&DMALDIhigh-throughput

Targeted, scalable glycoproteomics for hypothesis testing in R&D. High-throughput glycoprofiling in biotherapeutic lead selection. Speed Applicable to high throughput compound screening at >5,000/day Flexibility Choice between preconfigured biomarker panels and user-defined customization Turnkey Complete, accessible, ease-of use, end-to-end solution suite for pharma biotech Sensitivity Providing microheterogeneity glycopeptide characterization at picomolar sensitivity GlycoTyper is the solution for customized high-volume glycosylation profiling of targeted glycoproteins. The platform is based on isolation of the glycoprotein of interest from biospecimens (body fluids or tissue/cell lysates) using a cognate affinity reagent conjugated to magnetic microparticles in a capture step. Following washes to remove all components of the sample that are not of interest, the captured glycoprotein is released from the magnetic beads, which are then removed from the reaction mixture. In the next step, a PNGase F digest is carried out which releases the N-glycans from the cognate glycoprotein. In a subsequent step, protein and glycans are separated and glycans are selectively spotted on to a MALDI carrier surface, the Bruker AnchorChip™ in a 384-microarray format. After application of matrix chemistry, the AnchorChip is then processed on either a timsTOF fleX or a neofleX™ instrument for N-glycan data acquisition. Data processing is subsequently carried out using Bruker's proprietary GlycoProcessor software package. While this approach does not capture information on glycosylation macroheterogeneity, it accurately